Literature DB >> 26853560

Tumor suppressor properties of the splicing regulatory factor RBM10.

Jordi Hernández1,2, Elias Bechara1,2, Doerte Schlesinger1, Javier Delgado1,2, Luis Serrano1,2,3, Juan Valcárcel1,2,3.   

Abstract

RBM10 is an RNA binding protein and alternative splicing regulator frequently mutated in lung adenocarcinomas. Recent results indicate that RBM10 inhibits proliferation of lung cancer cells by promoting skipping of exon 9 of the gene NUMB, a frequent alternative splicing change in lung cancer generating a negative regulator of Notch signaling. Complementing these observations, we show that knock down of RBM10 in human cancer cells enhances growth of mouse tumor xenografts, confirming that RBM10 acts as a tumor suppressor, while knock down of an oncogenic mutant version of RBM10 reduces xenograft tumor growth. A RBM10 mutation found in lung cancer cells, V354E, disrupts RBM10-mediated regulation of NUMB alternative splicing, inducing the cell proliferation-promoting isoform. We now show that 2 natural RBM10 isoforms that differ by the presence or absence of V354 in the second RNA Recognition Motif (RRM2), display similar regulatory effects on NUMB alternative splicing, suggesting that V354E actively disrupts RBM10 activity. Structural modeling localizes V354 in the outside surface of one α-helix opposite to the RNA binding surface of RBM10, and we show that the mutation does not compromise binding of the RRM2 domain to NUMB RNA regulatory sequences. We further show that other RBM10 mutations found in lung adenocarcinomas also compromise regulation of NUMB exon 9. Collectively, our previous and current results reveal that RBM10 is a tumor suppressor that represses Notch signaling and cell proliferation through the regulation of NUMB alternative splicing.

Entities:  

Keywords:  Lung cancer; NUMB; Notch; RBM10; splicing

Mesh:

Substances:

Year:  2016        PMID: 26853560      PMCID: PMC4841610          DOI: 10.1080/15476286.2016.1144004

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  24 in total

1.  OCRE: a novel domain made of imperfect, aromatic-rich octamer repeats.

Authors:  Isabelle Callebaut; Jean-Paul Mornon
Journal:  Bioinformatics       Date:  2004-10-14       Impact factor: 6.937

2.  The Ewing sarcoma protein regulates DNA damage-induced alternative splicing.

Authors:  Maria Paola Paronetto; Belén Miñana; Juan Valcárcel
Journal:  Mol Cell       Date:  2011-08-05       Impact factor: 17.970

Review 3.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

4.  Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.

Authors:  Christine M Misquitta-Ali; Edith Cheng; Dave O'Hanlon; Ni Liu; C Jane McGlade; Ming Sound Tsao; Benjamin J Blencowe
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

5.  Prediction of water and metal binding sites and their affinities by using the Fold-X force field.

Authors:  Joost W H Schymkowitz; Frederic Rousseau; Ivo C Martins; Jesper Ferkinghoff-Borg; Francois Stricher; Luis Serrano
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

6.  The gene encoding the splicing factor SF2/ASF is a proto-oncogene.

Authors:  Rotem Karni; Elisa de Stanchina; Scott W Lowe; Rahul Sinha; David Mu; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2007-02-18       Impact factor: 15.369

Review 7.  NUMB-ing down cancer by more than just a NOTCH.

Authors:  Salvatore Pece; Stefano Confalonieri; Pascale R Romano; Pier Paolo Di Fiore
Journal:  Biochim Biophys Acta       Date:  2010-10-16

8.  Alterations of the Notch pathway in lung cancer.

Authors:  Britta Westhoff; Ivan N Colaluca; Giovanni D'Ario; Maddalena Donzelli; Daniela Tosoni; Sara Volorio; Giuseppe Pelosi; Lorenzo Spaggiari; Giovanni Mazzarol; Giuseppe Viale; Salvatore Pece; Pier Paolo Di Fiore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

9.  A bichromatic fluorescent reporter for cell-based screens of alternative splicing.

Authors:  James P Orengo; Donnie Bundman; Thomas A Cooper
Journal:  Nucleic Acids Res       Date:  2006-11-16       Impact factor: 16.971

10.  Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK.

Authors:  Pablo J Fernández-Marcos; Daniel Herranz; Antonio Maraver; Maribel Muñoz-Martin; Gonzalo Gomez-Lopez; Marta Cañamero; Francisca Mulero; Diego Megías; Marta Sanchez-Carbayo; Jie Shen; Montserrat Sanchez-Cespedes; Teresa Palomero; Adolfo Ferrando; Manuel Serrano
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

View more
  45 in total

1.  Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence.

Authors:  Tihana Ibrahimpasic; Bin Xu; Iñigo Landa; Snjezana Dogan; Sumit Middha; Venkatraman Seshan; Shyam Deraje; Diane L Carlson; Jocelyn Migliacci; Jeffrey A Knauf; Brian Untch; Michael F Berger; Luc Morris; R Michael Tuttle; Timothy Chan; James A Fagin; Ronald Ghossein; Ian Ganly
Journal:  Clin Cancer Res       Date:  2017-06-20       Impact factor: 12.531

2.  Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Authors:  Xiaohong Han; Rongrong Luo; Lin Wang; Lei Zhang; Tao Wang; Yan Zhao; Shanshan Xiao; Nan Qiao; Chi Xu; Lieming Ding; Zhishang Zhang; Yuankai Shi
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  RNA-binding proteins in human genetic disease.

Authors:  Fátima Gebauer; Thomas Schwarzl; Juan Valcárcel; Matthias W Hentze
Journal:  Nat Rev Genet       Date:  2020-11-24       Impact factor: 53.242

4.  Aberrant RNA Splicing in Cancer.

Authors:  Luisa Escobar-Hoyos; Katherine Knorr; Omar Abdel-Wahab
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

Review 5.  Roles and mechanisms of alternative splicing in cancer - implications for care.

Authors:  Sophie C Bonnal; Irene López-Oreja; Juan Valcárcel
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

Review 6.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

7.  Genetics of personalized medicine: cancer and rare diseases.

Authors:  Inês Teles Siefers Alves; Manuel Condinho; Sónia Custódio; Bruna F Pereira; Rafael Fernandes; Vânia Gonçalves; Paulo J da Costa; Rafaela Lacerda; Ana Rita Marques; Patrícia Martins-Dias; Gonçalo R Nogueira; Ana Rita Neves; Patrícia Pinho; Raquel Rodrigues; Eva Rolo; Joana Silva; André Travessa; Rosário Pinto Leite; Ana Sousa; Luísa Romão
Journal:  Cell Oncol (Dordr)       Date:  2018-04-09       Impact factor: 6.730

Review 8.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

9.  Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.

Authors:  Michael Seiler; Shouyong Peng; Anant A Agrawal; James Palacino; Teng Teng; Ping Zhu; Peter G Smith; Silvia Buonamici; Lihua Yu
Journal:  Cell Rep       Date:  2018-04-03       Impact factor: 9.423

Review 10.  RNA splicing factors as oncoproteins and tumour suppressors.

Authors:  Heidi Dvinge; Eunhee Kim; Omar Abdel-Wahab; Robert K Bradley
Journal:  Nat Rev Cancer       Date:  2016-06-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.